Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Burkitt's leukemia or lymphoma (new diagnosis)~* Written informed consent~* Age \> 15 years~Exclusion Criteria:~* pre-treated Burkitt's leukemia or lymphoma~* psychiatric disorders~* active second malignancy~* pregnancy~* absence of patient's written informed consent~* participation in other studies that interfere with the study therapy

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).